Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 29372


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Diagnostic
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29372

License Grant
Through a purchase Agreement, the Company acquired rights related to certain treatment for scleroderma. The Company is obligated to pay a royalty on our net revenue from sales of Actimmune for the treatment of scleroderma.
License Property
Scleroderma is an autoimmune disease of the connective tissue. Autoimmune diseases are illnesses which occur when the body's tissues are attacked by its own immune system.

Actimmune® (interferon gamma-1b) is a bio-engineered interferon gamma, a naturally occurring human protein that acts as a biologic response modifier that stimulates the immune system and has direct effect on various cells in the body.

IPSCIO Record ID: 27553

License Grant
Under the License Agreement with the Licensor, the original developer of Actimmune, the Irish Licensee is obligated to pay royalties to the Licensor on its net sales of Actimmune.
License Property
A bioengineered form of interferon gamma, which acts as a biologic response modifier bystimulating the human immune system. It is approved by the FDA for patients with chronic granulomatous disease (CGD)and severe, malignant osteopetrosis.
Field of Use
Biopharmaceutical sales company.

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.

IPSCIO Record ID: 7160

License Grant
The Licensee obtained a License from the Licensor through Connetics Corporation for patents relating to Actimmune.

Under this Agreement the Licensee has the exclusive License to develop and commercialize Actimmune in the United States and Canada for the treatment and prevention of all human diseases and conditions, including infectious diseases, pulmonary fibrosis and cancer, but excluding arthritis and cardiac and cardiovascular diseases and conditions.

In Japan, the Licensee have the exclusive License rights to commercialize Actimmune for the treatment and prevention of all infectious diseases caused by fungal, bacterial or viral agents, including in patients with CGD or osteoporosis.

The Licensee also has a non-exclusive License to make or have made, Actimmune for clinical and commercial purposes within our field of use in the United States and Canada.

IPSCIO Record ID: 159507

License Grant
The Company has a royalty agreement with Licensee, pursuant to which it is to receive a royalty on Licensees net sales of interferon and and transfer factor and products using interferon and transfer factor.  

The Board of Directors of Licensee and the Company have authorized amending the Royalty Agreement in consideration of the elimination of indebtedness of Licensee to the Company and of the promises and covenants set forth herein and for other good and valuable consideration, the parties agree to the following but not limited to; modifying the royalty section, extended the term, and rescinded a section.

License Property
Licensed Product shall mean Interferon, Transfer Factor and all products or any substance or group of substances which involve and include Interferon or Transfer Factor or any part of which product or any substance or group of substances includes Interferon or Transfer Factor.

Interferon shall mean and include a protein substance currently characterized as a viral neutralizing protein substance, whether produced naturally by lymphocytes, connective (fibroblast) tissue, including alpha, beta, and gamma interferon, and whether produced naturally or through a genetic engineering process.

Transfer Factor shall mean and include any lymphokine which exhibits specific biological activity for the protection of the body from viruses which is now recognized as mobilizing the natural immunological defense system of the body, whether the transfer factor is produced naturally from lymphokines or from other natural substances or whether produced through genetic engineering technology.

Field of Use
This agreement pertains the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.